OTC antihistamines
Executive Summary
Are expected to be key topic during April 8 hearing on OTC products convened by Rep. Weiss's (D-N.Y.) House intergovernmental affairs subcommittee. FDA is re-examining the Category I status of OTC antihistamines and particularly its earlier decision to let data on chlorpheniramine support claims for a variety of antihistamines ("The Pink Sheet" March 30, p. 3).